

CD2 Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
CD2 Concentrate	FP-A005-01	0.1 ml
CD2 Concentrate	FP-A005-10	1 ml
CD2 Predilute	FP-A005-70	7ml

Description

Cluster of differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.

Specifications

Clone	IHC531
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Tonsil
Dilution Range	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the corresponding user manual for detection system

Result




Figure CD2 on Tonsil



Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

The product is for research use only. Do not use for diagnosis purpose. Ensure proper handling procedures are used with all reagents. Always wear laboratory coats, disposable gloves, and other appropriate laboratory equipment when handling reagents. Do not ingest reagents, and avoid contact with eyes and mucous membranes. Wash eyes with copious amounts of water if contact occurs.

References

1. **Went P**, et al. “Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.” *J Clin Oncol.* 2006; 24:2472-2479.
2. **Aguilera NS**, et al. “Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens.” *Arch Pathol Lab Med.* 2006; 130:1772-9.
3. **Barrionuevo C**, et al. “Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru.” *Appl Immunohistochem Mol Morphol.* 2007; 15:38-44.
4. **Bovenschen HJ**, et al. “Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.” *Br J Dermatol.* 2005; 153:72-8.
5. **Foon KA**, et al. “Immunologic classification of leukemia and lymphoma.” *Blood* 1986; 68:1- 31.

Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for assistance with more questions regarding this product.